Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and markets pain management medications. The company is headquartered in Stoughton, Massachusetts.
| Revenue (TTM) | $808.21M |
| Gross Profit (TTM) | $722.93M |
| EBITDA | $405.25M |
| Operating Margin | 5.65% |
| Return on Equity | 17.60% |
| Return on Assets | 5.76% |
| Revenue/Share (TTM) | $25.30 |
| Book Value | $9.60 |
| Price-to-Book | 2.34 |
| Price-to-Sales (TTM) | 0.93 |
| EV/Revenue | 2.101 |
| EV/EBITDA | 4.38 |
| Quarterly Earnings Growth (YoY) | -46.60% |
| Quarterly Revenue Growth (YoY) | 6.30% |
| Shares Outstanding | $32.56M |
| Float | $29.77M |
| % Insiders | 1.15% |
| % Institutions | 129.84% |
Volatility is currently expanding
The consensus price target hints at an 111.4% upside potential for Collegium Pharmaceutical (COLL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
ARDX, LUV and COLL have been added to the Zacks Rank #5 (Strong Sell) List on October 7th, 2026.
STOUGHTON, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, launched Start Talking ADHD, an online resource hub offering practical guides to people living with attention-deficit/hyperactivity disorder (ADHD), and the families who support them.
Collegium Pharmaceutical, Inc. (COLL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
STOUGHTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today announced that its management will participate in the following investor conferences:
STOUGHTON, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $50 million of the Company's common stock. Collegium will execute the ASR as part of the $150 million share repurchase program authorized by its Board of Directors in July 2025. Upon completion of this ASR, Collegium will have $100 million remaining under the program.
Collegium Pharmaceutical, Inc. (COLL) Q2 2026 Earnings Call Transcript
Although the revenue and EPS for Collegium Pharmaceutical (COLL) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.92 per share, beating the Zacks Consensus Estimate of $1.68 per share. This compares to earnings of $1.68 per share a year ago.
Collegium Pharmaceutical NASDAQ: COLL reported second-quarter 2026 net product revenue of $199.9 million, up 6% from a year earlier, as growth in its ADHD franchise and BELBUCA helped offset lower revenue from the NUCYNTA pain franchise.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on COLL and any ticker you trade — then tracks every position and per-strategy win rate.
